Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Authors: Reyes Bernabé, Stephen V. Liu, Amparo Sánchez-Gastaldo, Miriam Alonso García

Source: Oncology and Therapy, Vol 12, Iss 1, Pp 175-182 (2024)

Subject Terms: Atezolizumab, Carboplatin, Etoposide, Long-term survival, Small-cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2366-1070; https://doaj.org/toc/2366-1089

Access URL: https://doaj.org/article/7371186711bd4b1a9cf04d73272dbfcf

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Authors: Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, Mariano Provencio

Source: ERJ Open Research, Vol 9, Iss 6 (2023)

Subject Terms: Medicine

File Description: electronic resource

Relation: http://openres.ersjournals.com/content/9/6/00468-2023.full; https://doaj.org/toc/2312-0541

Access URL: https://doaj.org/article/a612acb88ba047f79e4cc339b0b86a9c

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Authors: Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/11/2/e006127.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis

Authors: Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD

Source: JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)

Subject Terms: Small-cell lung cancer, TNM staging, Overall survival, Long-term survival, Prognostic factor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364321001259; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Authors: Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro

Source: Pharmaceuticals, Vol 15, Iss 5, p 533 (2022)

Subject Terms: atezolizumab, immune checkpoint inhibitors (ICIs), immunotherapy, nivolumab, non-small cell lung cancer (NSCLC), real-world data, Medicine, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.mdpi.com/1424-8247/15/5/533; https://doaj.org/toc/1424-8247

Access URL: https://doaj.org/article/6c4ab7e0320e4541932945c15fccdbcf

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

Authors: Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo

Source: BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)

Subject Terms: Osimertinib, Real-world data, EGFR-activating mutations, T790M EGFR mutation, Second line, Non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d